GlassScriptPhysician profile
Alvand John Sehat
NPI 1043770829
$2,642.33
in general payments reported to CMS, 2019-2025
10 companies · $2,642 in 2025
The $2,642 reported for 2025 was more than what 85% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,254 · Travel and Lodging: $707 · Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,254.19 |
| Travel and Lodging | $706.57 |
| Food and Beverage | $681.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,906.09 | 2025 | |
| Stryker Corporation | $254.19 | 2025 | |
| Acera Surgical, INC. | $186.18 | 2025 | Restrata Wound Matrix |
| Davol INC. | $159.03 | 2025 | Phasix Mesh |
| Kerecis Limited | $33.69 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Ethicon US, LLC | $32.63 | 2025 | Prolene, Surgicel Nu-Knit |
| Takeda Pharmaceuticals U.S.A., INC. | $21.04 | 2025 | Gattex |
| Boston Scientific Corporation | $20.65 | 2025 | Apollo Esg Nxt System |
| Novo Nordisk INC | $14.84 | 2025 | Wegovy |
| Vertex Pharmaceuticals Incorporated | $13.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvand Sehat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.